Results 81 to 90 of about 83,328 (323)

Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant

Animal Models and Experimental Medicine, EarlyView.
A 6½‐year‐old girl was diagnosed with a medulloblastoma, SHH activated, subtype 3 and TP53 mutant (somatic). After surgery and chemotherapy, she was monitored with quarterly magnetic resonance imaging (MRI) scans and remained free of disease for almost 4 years.
Daniel Antunes Moreno, Bruna Minniti Mançano, Mirella Baroni, Eric Allison Philot, Felipe Antonio de Oliveira Garcia, Murilo Bonatelli, Flávia Escremim de Paula, Iara Viana Vidigal Santana, Gustavo Ramos Teixeira, Mauricio Yamanari, Luciane Sussuchi da Silva, André Escremim de Paula, Augusto Perazzolo Antoniazzi, Adrian Willig, Xiaobin Xing, Zhenyu Xu, Lucas Lourenço, Carlos Almeida Junior, Silvia Aparecida Teixeira, Rui Manuel Reis   +19 more
wiley   +1 more source

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. [PDF]

PLoS ONE, 2018
Expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative regulator of T-cell function, is increased in chronic HIV-1 infection. It was hypothesized that CTLA-4 blockade may enhance immune response to HIV-1 and result in better control of ...
Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy   +6 more
doaj   +1 more source

OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA [PDF]

, 2021
Martin Reck, Tudor‐Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Arnaud Scherpereel, Shun Lu, Thomas John, David P. Carbone, S. Meadows–Shropshire, Jiarui Yan, Luis Paz‐Ares   +18 more
openalex   +1 more source

Toward Customization of Pickering Emulsion Nanocarriers for Personalized Delivery of Therapeutics in Cancer Treatments: A Review

Advanced NanoBiomed Research, EarlyView.
Pickering emulsion‐based nanocarriers are emerging as a disruptive innovation in oncology. Their unique structural and functional attributes have now positioned these systems at the forefront of next‐generation smart delivery platforms, capable of improving therapeutic precision, efficacy, and safety.
Nutan Shukla, Aayushi Chanderiya, Ratnesh Das, Supriya Vyas, Elizaveta Mukhanova, Alexander Soldatov, Samuel Adeloju   +6 more
wiley   +1 more source

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Journal of Translational Medicine, 2012
Background Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ...
Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S   +8 more
doaj   +1 more source

Full Issue: Volume 13, Issue 1 - Winter 2018 [PDF]

, 2018
Full Issue: Volume 13, Issue 1 - Winter ...

core   +1 more source

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database

British Journal of Clinical Pharmacology, EarlyView.
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya, Ryohkan Funakoshi, Koichi Masuyama, Nariyasu Mano, Satoko Hori, Taku Obara   +5 more
wiley   +1 more source

Biological therapy in the treatment of melanoma [PDF]

, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile, Georgescu, Simona Roxana, Ghita, Ela, Ioghen, Mihaela Roxana, Ion, Alexandra-Florentina, Mitran, Cristina-Iulia, Mitran, Madalina-Irina, Sarbu, Maria Isabela, Tampa, Mircea   +8 more
core   +3 more sources

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for ImmunoTherapy of Cancer
Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology.
David P. Carbone, T. Ciuleanu, M. Schenker, M. Cobo, S. Bordenave, Ó. Juan-Vidal, J. Menezes, Niels Reinmuth, E. Richardet, Ying Cheng, H. Mizutani, E. Felip, B. Żurawski, A. Alexandru, L. Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, Nan Hu, Tuli De, Irene Santi, J. Penrod, Yong Yuan, Adam Lee, Martin Reck   +25 more
semanticscholar   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source